About: The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 27 August 2008

Attributes	Values
rdf:type	Item
description	videnskabelig artikel (da) article científic (ca) articolo scientifico (it) artigo científico (pt) bilimsel makale (tr) vedecký článok (sk) vetenskaplig artikel (sv) vědecký článek (cs) wetenschappelijk artikel (nl) wissenschaftlicher Artikel (de) научни чланак (sr) article scientifique (fr) artículu científicu espublizáu en 2008 (ast) наукова стаття, опублікована в серпні 2008 (uk) scientific article published on 27 August 2008 (en) مقالة علمية نشرت في 27 أغسطس 2008 (ar)
publication date	wds:Q37254721-A593DD1D-C484-4B31-9B9D-26A96A23C416
publication date	2008-08-27 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q37254721-0F1E7FDA-16C4-42A0-9567-0D197F18C15A
language of work or name	English
author name string	wds:Q37254721-61654A14-FEC3-4FFD-BD7E-01FC50A25E46 wds:Q37254721-64A77297-C9ED-4CC3-A7E7-AC616D3A083C wds:Q37254721-988EEEA6-8D86-468F-8C26-81F9AC9F796A
author name string	T R Einarson E C Keystone J P Leombruno
rdfs:label	The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events (en) The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events (nl) The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events (ast)
skos:prefLabel	The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events (en) The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events (nl) The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events (ast)
name	The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events (en) The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events (nl) The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events (ast)
title	wds:Q37254721-DD07CCF0-5363-4E36-9B59-E425B4A76B4A
title	The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events (en)
page(s)	wds:Q37254721-F8AB9FAE-EF43-496F-9F4E-6DE0BAF8E165
page(s)	1136-1145
instance of	wds:Q37254721-4007a838-98d9-47a2-a117-4017286f61aa wds:Q37254721-5325135C-7A7E-4A1B-8085-8793B5B07C8F wds:Q37254721-ad3aa9d2-54a0-4c76-a00c-667d2a911947
instance of	meta-analysis review article scholarly article
main subject	wds:Q37254721-177a2940-d29a-42c5-b496-b8f4b45cd27e wds:Q37254721-1A21B457-C691-445F-9B09-765EB4024DC0
main subject	wd:Q18032037 rheumatoid arthritis
PubMed ID	wds:Q37254721-58E60342-D4CE-4945-BD70-2039D099348B
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/18753157
PubMed ID	18753157
published in	wds:Q37254721-17D8A4CC-AFD6-4057-964D-67D2DD74F9C5
published in	Annals of the Rheumatic Diseases
issue	wds:Q37254721-C7D656FE-99E8-4EC2-B7F9-C1B70235437D
volume	wds:Q37254721-9C976B4C-A908-45E7-A1DC-17D4F53168D8
issue	7
volume	68
DOI	wds:Q37254721-13266EA0-236F-440F-ADB4-F7FB70C7E05F
DOI	http://dx.doi.org/10.1136/ARD.2008.091025
DOI	10.1136/ARD.2008.091025
ResearchGate publication ID	wds:Q37254721-04C8C6B6-CAAC-493C-949A-CC0DB658732A
ResearchGate publication ID	23219769
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q37254721
is cites work of	Risk factors for total joint arthroplasty infection in patients receiving tumor necrosis factor α-blockers: a case-control study Rheumatoid arthritis Hierarchical network meta-analysis models to address sparsity of events and differing treatment classifications with regard to adverse outcomes Psoriasis and comorbidities: links and risks Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases Biologics-based therapy for the treatment of rheumatoid arthritis The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials TNF-α Polymorphisms in Juvenile Idiopathic Arthritis: Which Potential Clinical Implications? New insights into the impact of neuro-inflammation in rheumatoid arthritis Assessing infection risk with biologic agents in RA: methodological challenges Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFα inhibitors and rituximab Rheumatoid arthritis, anti-tumour necrosis factor treatment, and risk of squamous cell and basal cell skin cancer: cohort study based on nationwide prospectively recorded data from Sweden The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: longitudinal results from the British Society for Rheumatology Biologics Register Continuation of TNF blockade in patients with inflammatory rheumatic disease. An observational study on surgical site infections in 1,596 elective orthopedic and hand surgery procedures Is there truly a risk of lymphoma from biologic therapies? Inflammation and cancer: advances and new agents Biologic agents in rheumatology: unmet issues after 200 trials and $200 billion sales Anticytokine therapy in systemic lupus erythematosus Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis 74-week follow-up of safety of infliximab in patients with refractory rheumatoid arthritis Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease Malignancy as a comorbidity in rheumatic diseases Adalimumab in the treatment of rheumatoid arthritis Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with specia Cancer risk of anti-TNF-α at recommended doses in adult rheumatoid arthritis: a meta-analysis with intention to treat and per protocol analyses Choice of Biologic Therapy for Patients with Rheumatoid Arthritis: The Infection Perspective Beyond tumor necrosis factor inhibition: the expanding pipeline of biologic therapies for inflammatory diseases and their associated infectious sequelae Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis Safety of Anti-TNF Therapies in Immune-Mediated Inflammatory Diseases: Focus on Infections and Malignancy. Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient? Evaluation of the RABBIT Risk Score for serious infections The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment Risk of infections in bronchiectasis during disease-modifying treatment and biologics for rheumatic diseases

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 172 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software